Sareum Hldgs Plc
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more
Sareum Hldgs Plc (SAR) - Net Assets
Latest net assets as of June 2025: £2.28 Million GBP
Based on the latest financial reports, Sareum Hldgs Plc (SAR) has net assets worth £2.28 Million GBP as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (£4.23 Million) and total liabilities (£1.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | £2.28 Million |
| % of Total Assets | 53.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | -18.53% |
| 10-Year Change | 22.19% |
| Growth Volatility | 76.38 |
Sareum Hldgs Plc - Net Assets Trend (2004–2025)
This chart illustrates how Sareum Hldgs Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sareum Hldgs Plc (2004–2025)
The table below shows the annual net assets of Sareum Hldgs Plc from 2004 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | £2.28 Million | +7.71% |
| 2024-06-30 | £2.11 Million | +83.35% |
| 2023-06-30 | £1.15 Million | -73.38% |
| 2022-06-30 | £4.33 Million | +54.95% |
| 2021-06-30 | £2.80 Million | +54.97% |
| 2020-06-30 | £1.80 Million | +64.83% |
| 2019-06-30 | £1.09 Million | -32.98% |
| 2018-06-30 | £1.63 Million | -30.40% |
| 2017-06-30 | £2.35 Million | +25.87% |
| 2016-06-30 | £1.86 Million | +0.02% |
| 2015-06-30 | £1.86 Million | +8.17% |
| 2014-06-30 | £1.72 Million | +292.27% |
| 2013-06-30 | £439.10K | -8.59% |
| 2012-06-30 | £480.38K | -45.16% |
| 2011-06-30 | £876.00K | +67.50% |
| 2010-06-30 | £523.00K | +59.94% |
| 2009-06-30 | £327.00K | -76.64% |
| 2008-06-30 | £1.40 Million | +2.49% |
| 2007-06-30 | £1.37 Million | +14.31% |
| 2006-06-30 | £1.20 Million | -9.40% |
| 2005-06-30 | £1.32 Million | +1616.09% |
| 2004-06-30 | £-87.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sareum Hldgs Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2866900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | £1.68 Million | 73.78% |
| Other Comprehensive Income | £363.00K | 15.94% |
| Other Components | £29.02 Million | 1274.48% |
| Total Equity | £2.28 Million | 100.00% |
Sareum Hldgs Plc Competitors by Market Cap
The table below lists competitors of Sareum Hldgs Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ClearSign Combustion Corporation
NASDAQ:CLIR
|
$28.71 Million |
|
SIKRI GROUP ASA NK-02
F:57U0
|
$28.71 Million |
|
Azimut Exploration Inc
OTCQX:AZMTF
|
$28.72 Million |
|
MoneyHero Limited Class A Ordinary Shares
NASDAQ:MNY
|
$28.73 Million |
|
VELA TECHNOL.PLC LS-0001
F:IBNN
|
$28.70 Million |
|
Mahamaya Steel Industries Limited
NSE:MAHASTEEL
|
$28.70 Million |
|
THERANEXUS EO -25
F:3VG
|
$28.69 Million |
|
Kao Hsiung Chang Iron & Steel Corp
TW:2008
|
$28.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sareum Hldgs Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,114,000 to 2,277,000, a change of 163,000 (7.7%).
- Net loss of 4,438,000 reduced equity.
- New share issuances of 4,701,000 increased equity.
- Other comprehensive income increased equity by 31,000.
- Other factors decreased equity by 131,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | £-4.44 Million | -194.91% |
| Share Issuances | £4.70 Million | +206.46% |
| Other Comprehensive Income | £31.00K | +1.36% |
| Other Changes | £-131.00K | -5.75% |
| Total Change | £- | 7.71% |
Book Value vs Market Value Analysis
This analysis compares Sareum Hldgs Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 813.57x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-06-30 | £-0.01 | £15.00 | x |
| 2005-06-30 | £0.22 | £15.00 | x |
| 2006-06-30 | £0.17 | £15.00 | x |
| 2007-06-30 | £0.14 | £15.00 | x |
| 2008-06-30 | £0.11 | £15.00 | x |
| 2009-06-30 | £0.02 | £15.00 | x |
| 2010-06-30 | £0.02 | £15.00 | x |
| 2011-06-30 | £0.03 | £15.00 | x |
| 2012-06-30 | £0.02 | £15.00 | x |
| 2013-06-30 | £0.01 | £15.00 | x |
| 2014-06-30 | £0.05 | £15.00 | x |
| 2015-06-30 | £0.05 | £15.00 | x |
| 2016-06-30 | £0.04 | £15.00 | x |
| 2017-06-30 | £0.04 | £15.00 | x |
| 2018-06-30 | £0.03 | £15.00 | x |
| 2019-06-30 | £0.02 | £15.00 | x |
| 2020-06-30 | £0.03 | £15.00 | x |
| 2021-06-30 | £0.04 | £15.00 | x |
| 2022-06-30 | £0.06 | £15.00 | x |
| 2023-06-30 | £0.02 | £15.00 | x |
| 2024-06-30 | £0.03 | £15.00 | x |
| 2025-06-30 | £0.02 | £15.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sareum Hldgs Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -194.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.86x
- Recent ROE (-194.91%) is below the historical average (-101.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | -561.90% | 0.03x | 0.00x | £-109.30K |
| 2005 | -94.24% | -374.40% | 0.19x | 1.36x | £-1.37 Million |
| 2006 | -52.22% | -42.28% | 0.83x | 1.49x | £-743.50K |
| 2007 | -38.58% | -21.33% | 0.97x | 1.86x | £-663.60K |
| 2008 | -120.86% | -112.57% | 0.82x | 1.31x | £-1.83 Million |
| 2009 | -328.44% | 0.00% | 0.00x | 1.16x | £-1.11 Million |
| 2010 | -108.80% | 0.00% | 0.00x | 1.19x | £-621.30K |
| 2011 | -64.84% | 0.00% | 0.00x | 1.11x | £-655.60K |
| 2012 | -135.43% | 0.00% | 0.00x | 1.26x | £-698.60K |
| 2013 | -122.78% | 0.00% | 0.00x | 1.18x | £-583.04K |
| 2014 | -44.29% | 0.00% | 0.00x | 1.04x | £-935.12K |
| 2015 | -67.38% | 0.00% | 0.00x | 1.04x | £-1.44 Million |
| 2016 | -56.24% | 0.00% | 0.00x | 1.05x | £-1.23 Million |
| 2017 | 17.07% | 0.00% | 0.00x | 1.07x | £165.78K |
| 2018 | -90.01% | 0.00% | 0.00x | 1.11x | £-1.63 Million |
| 2019 | -132.74% | 0.00% | 0.00x | 1.13x | £-1.56 Million |
| 2020 | -54.66% | -2088.62% | 0.02x | 1.11x | £-1.17 Million |
| 2021 | -53.68% | 0.00% | 0.00x | 1.10x | £-1.78 Million |
| 2022 | -50.15% | 0.00% | 0.00x | 1.11x | £-2.61 Million |
| 2023 | -276.84% | 0.00% | 0.00x | 1.75x | £-3.31 Million |
| 2024 | -161.78% | 0.00% | 0.00x | 1.31x | £-3.63 Million |
| 2025 | -194.91% | 0.00% | 0.00x | 1.86x | £-4.67 Million |
Industry Comparison
This section compares Sareum Hldgs Plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,807,025
- Average return on equity (ROE) among peers: -134.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sareum Hldgs Plc (SAR) | £2.28 Million | 0.00% | 0.86x | $28.71 Million |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $10.53K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $3.12K |
| Arecor Therapeutics PLC (AREC) | $773.79K | -355.70% | 4.54x | $3.33K |
| Bioventix (BVXP) | $4.20 Million | 36.18% | 0.07x | $9.85K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $741.00K | -0.02% | 3.16x | $747.56 |
| Fusion Antibodies PLC (FAB) | $1.46 Million | 79.21% | 0.28x | $2.07K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $27.00K |
| Futura Medical (FUM) | $9.72 Million | -50.98% | 0.21x | $424.60 |
| hVIVO plc (HVO) | $2.86 Million | -195.31% | 2.17x | $5.18K |
| International Biotechnology Trust plc (IBT) | $66.95 Million | 14.71% | 0.00x | $1.08K |